Clinical progress in stem cell therapy for end-stage liver disease
10.3760/cma.j.cn501113-20241018-00548
- VernacularTitle:干细胞治疗终末期肝病的临床进展
- Author:
Yuefei PAN
1
;
Yunbo XIE
1
;
Lei SHI
1
;
Ming SHI
1
;
Fusheng WANG
1
Author Information
1. 解放军总医院第五医学中心感染病医学部 国家感染性疾病临床医学研究中心，北京 100039
- Publication Type:Journal Article
- Keywords:
Stem cell;
End-stage liver disease;
Liver cirrhosis;
Liver failure;
Therapeutic
- From:
Chinese Journal of Hepatology
2024;32(12):1060-1066
- CountryChina
- Language:Chinese
-
Abstract:
End-stage liver disease includes liver failure and decompensated cirrhosis resulting from various etiologies and often leads to patient mortality due to complications and clinical symptoms such as severe jaundice, ascites, hepatic encephalopathy, coagulopathy, and hepatorenal syndrome. Liver transplantation is currently regarded as the most effective treatment, but its clinical application is limited by the shortage of donors, elevated expenses, and post-transplant rejection. Stem cells are a group of cells with multidirectional differentiation potential and self-renewal ability, which can improve the clinical indicator outcomes through mechanisms such as immunoregulation and promotion of tissue repair in patients with end-stage liver disease. Clinical trials of stem cell therapy have achieved a series of results for end-stage liver disease, proving the safety and effectiveness of stem cell therapy. This article reviews the clinical studies that have been registered and published at home and abroad and provides a reference for the clinical plan on stem cell therapy for end-stage liver disease.
